Olaratumab for the treatment of patients (pts) with advanced/metastatic soft tissue sarcoma (STS): Treatment patterns in the United States (US) during the first year post-approval.

e23535Background: Olaratumab (olara) is a fully human platelet-derived growth factor receptor alpha (PDGFR-α) receptor antagonist that received US Food and Drug Administration (FDA) accelerated app...